“As we look to the second half for pharma biotech, we actually think it will be a little better, even though we saw a nice step-up in quarter.”

How to check this claim

Look at: Pharma/biotech end-market revenue growth rate for Thermo Fisher (as reported/discussed by management, typically organic growth for that end market)

It came true if: Second-half 2026 pharma/biotech growth rate higher than the growth rate reported for the first half/second quarter of 2026

Where: Management commentary and segment/end-market discussion on Q3 2026 and Q4 2026 earnings calls

Verify independently

SEC filings for TMO ↗ · Claim quote is verbatim from the 2026Q2 earnings call.